ROMAINVILLE, France--(BUSINESS WIRE)--Parc Biocitech, Romainville, June 10, 2009 — On March 13, 2008, the genome engineering company Cellectis SA (Alternext: ALCLS) initiated a patent infringement lawsuit in the U.S. District Court in North Carolina against Precision Biosciences Inc., for infringing two of its patents directed to the use of molecules known as megaucleases in recombinant biotechnology. These two patents-in-suit, U.S. Patent Nos. 7,309,605 and 6,610,545, are exclusively licensed from Institut Pasteur, a world-renowned, not-for-profit research institution, and are part of a portfolio of patents and applications in the endonuclease field that Cellectis owns or to which it has exclusive rights. Currently, Cellectis holds a portfolio of 42 granted patents, with more than 130 applications for additional patents pending.
